🇺🇸 Carrilizumab in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 1
Most-reported reactions
- Palmar-Plantar Erythrodysaesthesia Syndrome — 1 report (100%)
Other Other approved in United States
Frequently asked questions
Is Carrilizumab approved in United States?
Carrilizumab does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Carrilizumab in United States?
First Affiliated Hospital Xi'an Jiaotong University is the originator. The local marketing authorisation holder may differ — check the official source linked above.